NAD+ Precursors Robustly Boost Blood Levels but Fail to Consistently Improve Health in Humans

NAD+ is a critical molecule that declines 40-60% between ages 30 and 70. Supplements like NMN and NR reliably double circulating NAD+ levels in humans within 14 days, but clinical trials have not consistently shown the dramatic health improvements seen in mice.

NMN and NR approximately double circulating NAD+ after 14 days of supplementation (confirmed 2025). However, a meta-analysis found most clinically relevant outcomes not significantly different between NMN supplementation and control groups. The translation gap may involve: (1) CD38 NADase activity increasing with age, degrading NAD+ faster than replenished; (2) gut microbiome converting NMN/NR to nicotinic acid before absorption; (3) tissue-specific NAMPT pathway means systemic supplementation may not reach brain, heart, or muscle. FDA banned NMN as dietary supplement in 2022.

Why It Matters

NAD+ supplement market estimated at $500M-1B annually, growing 15-20%/year, largely without clinical validation. Age-related NAD+ decline implicated in heart failure (6.2M Americans), neurodegeneration (6.7M with Alzheimer's), and metabolic syndrome (34% of US adults).

Startup Approach

Build a precision NAD+ metabolism platform: measure individual patients' CD38 activity, NAMPT expression, and tissue-specific NAD+ levels. Develop combination therapies (NAD+ precursor + CD38 inhibitor + sirtuin activator) tailored to metabolic profiles. Run properly powered trials in aged populations (70+) with functional endpoints (grip strength, VO2max, cognitive tests).

NIH Funding

NIA actively funds NAD+ research. NIH Reporter shows 200+ active grants mentioning NAD+ and aging. NIA Interventions Testing Program has tested NAD+ precursors in mice.

Who's Working On It

David Sinclair Lab (Harvard, NMN pioneer), Charles Brenner (City of Hope, NR discoverer), Eduardo Chini (Mayo Clinic, CD38 inhibitors), Metro International Biotech (MIB-626), ChromaDex (Niagen/NR), Elysium Health (Basis)